FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later-Reference-Cited by-同舟云学术

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later

Published:2019-03-12 Issue:5 Volume:21 Page:1073-1078
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

McGuire Darren K.¹^ORCID,Marx Nikolaus²,Johansen Odd Erik³^ORCID,Inzucchi Silvio E.⁴,Rosenstock Julio⁵^ORCID,George Jyothis T.⁶

Affiliation:

1. Division of CardiologyUniversity of Texas Southwestern Medical Center Dallas Texas

2. Department of Internal Medicine IUniversity Hospital Aachen, RWTH Aachen University Aachen Germany

3. Clinical DevelopmentTherapeutic Area Cardiometabolism, Boehringer Ingelheim Asker Norway

4. Section of EndocrinologyYale University School of Medicine New Haven Connecticut

5. Dallas Diabetes Research Center at Medical City and University of Texas, Southwestern Medical Center Dallas Texas

6. Clinical DevelopmentTherapeutic Area Cardiometabolism, Boehringer Ingelheim Ingelheim Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13645

Reference47 articles.

1. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Diabetes Mellitus ‐ Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available atwww.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf(accessed October 8 2018).

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

5. Intarcia press‐release Oct 9th 2018.https://www.intarcia.com/media/media‐archive/press‐releases/intarcia‐announces‐successful‐cardiovascular‐safety‐results‐in‐p.html. Accessed Oct 9 2018.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future Drug Treatments for Type 2 Diabetes;Textbook of Diabetes;2024-01-12

2. 5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine;Diabetes, Obesity and Metabolism;2023-10-22

3. The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review;Cardiology Research;2023-08

4. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications;Life;2023-04-14

5. A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study;Advances in Therapy;2022-06-11